Home / IPHYF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does IPHYF make money? Does IPHYF have pricing power? What's the Earnings Whisper? Will IPHYF profit more as the business scales? What is IPHYF's management track record? Is IPHYF's current price justified?

Innate Pharma S.A.

$1.65 -$0.50 (-23.26%)

OTC · 14 Sep 2026 20:00 UTC

Previous Close

$1.65

Day Range

$1.65$2.25

Year Range

$1.37$2.25

Market Cap

154.94M

AVG Volume

111

Trailing/Forward PE

-2.8/-

PEG ratio

-0.08

Dividend Yield

Next Earnings Date

2026-09-17

Primary Exchange

Other OTC

Employee Count

IPHYF Employee Count by year
Period	Employee Count
2025	164
2024	181
2023	179
2022	211
2021	215
2020	245
2019	235

Free Cash Flow Yield

IPHYF Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-46.29%
Sep 26	-46.29%
Sep 26	-46.36%
Aug 26	-46.23%
Aug 26	-46.6%
Aug 26	-46.16%
Aug 26	-46.12%
Jul 26	-46.01%
Jul 26	-45.38%
Jul 26	-45.65%
Jul 26	-45.56%
Jul 26	-45.63%
Jun 26	-45.43%
Jun 26	-45.74%
Jun 26	-46.17%
Jun 26	-45.98%
May 26	-46.51%
May 26	-33.95%
May 26	-34.03%
May 26	-51.74%
May 26	-51.45%
Apr 26	-51.46%
Apr 26	-51.64%
Apr 26	-56.36%
Apr 26	-55.48%
Mar 26	-55.32%
Mar 26	-37.6%
Mar 26	-37.17%
Mar 26	-37.76%
Feb 26	-38.43%
Feb 26	-38.29%
Feb 26	-38.58%
Feb 26	-38.4%
Jan 26	-38.51%
Jan 26	-38.44%
Jan 26	-37.7%
Jan 26	-37.82%
Jan 26	-38.09%
Dec 25	-38.26%
Dec 25	-38.05%
Dec 25	-43.18%
Dec 25	-40.88%
Nov 25	-40.52%
Nov 25	-40.22%
Nov 25	-40.6%
Nov 25	-40.4%
Oct 25	-40.45%
Oct 25	-40.63%
Oct 25	-40.71%
Oct 25	-40.62%
Oct 25	-41.03%
Sep 25	-40.88%
Sep 25	-41.03%
Sep 25	-29.09%
Sep 25	-28.22%
Aug 25	-28.14%
Aug 25	-28.23%
Aug 25	-28.19%
Aug 25	-44.08%
Aug 25	-43.87%
Jul 25	-44.45%
Jul 25	-44.01%
Jul 25	-44.26%
Jul 25	-29.91%
Jun 25	-29.8%
Jun 25	-32.85%
Jun 25	-32.93%
Jun 25	-38.98%
May 25	-38.83%
May 25	-38.89%
May 25	-38.19%
May 25	-38.48%
May 25	-38.65%
Apr 25	-50.12%
Apr 25	-50.14%
Apr 25	-50.11%
Apr 25	-24.17%
Mar 25	-23.9%
Mar 25	-23.85%
Mar 25	-24.01%
Mar 25	-23.88%
Feb 25	-22.87%
Feb 25	-23.07%
Feb 25	-23.13%
Feb 25	-22.77%
Jan 25	-22.84%
Jan 25	-23.13%
Jan 25	-22.64%
Jan 25	-22.59%
Jan 25	-22.73%
Dec 24	-22.98%
Dec 24	-22.99%
Dec 24	-23.16%
Dec 24	-52.78%
Nov 24	-52.83%
Nov 24	-52.05%
Nov 24	-52.65%
Nov 24	-30.59%
Nov 24	-30.94%
Oct 24	-30.82%

Price to Sales

IPHYF Price to Sales by year
Period	Price to Sales
Sep 26	6.99
Sep 26	6.99
Sep 26	6.98
Aug 26	7
Aug 26	6.94
Aug 26	7.01
Aug 26	7.02
Jul 26	7.03
Jul 26	7.13
Jul 26	7.09
Jul 26	7.1
Jul 26	7.09
Jun 26	7.12
Jun 26	7.07
Jun 26	7.01
Jun 26	7.04
May 26	6.96
May 26	9.53
May 26	9.51
May 26	6.25
May 26	6.29
Apr 26	6.29
Apr 26	6.27
Apr 26	5.74
Apr 26	5.83
Mar 26	5.85
Mar 26	4.07
Mar 26	4.12
Mar 26	4.06
Feb 26	3.99
Feb 26	4
Feb 26	3.97
Feb 26	3.99
Jan 26	3.98
Jan 26	3.99
Jan 26	4.06
Jan 26	4.05
Jan 26	4.02
Dec 25	4.01
Dec 25	4.03
Dec 25	3.55
Dec 25	3.75
Nov 25	3.78
Nov 25	3.81
Nov 25	3.77
Nov 25	3.79
Oct 25	3.79
Oct 25	3.77
Oct 25	3.76
Oct 25	3.77
Oct 25	3.73
Sep 25	3.75
Sep 25	3.73
Sep 25	1.86
Sep 25	1.92
Aug 25	1.92
Aug 25	1.92
Aug 25	1.92
Aug 25	1.23
Aug 25	1.23
Jul 25	1.22
Jul 25	1.23
Jul 25	1.22
Jul 25	1.81
Jun 25	1.82
Jun 25	1.65
Jun 25	1.64
Jun 25	1.39
May 25	1.39
May 25	1.39
May 25	1.42
May 25	1.41
May 25	1.4
Apr 25	1.24
Apr 25	1.24
Apr 25	1.24
Apr 25	2.57
Mar 25	2.6
Mar 25	2.6
Mar 25	2.58
Mar 25	2.6
Feb 25	2.71
Feb 25	2.69
Feb 25	2.68
Feb 25	2.72
Jan 25	2.72
Jan 25	2.68
Jan 25	2.74
Jan 25	2.75
Jan 25	2.73
Dec 24	2.7
Dec 24	2.7
Dec 24	2.68
Dec 24	1.18
Nov 24	1.17
Nov 24	1.19
Nov 24	1.18
Nov 24	2.03
Nov 24	2.01
Oct 24	2.01

EV/EBITDA

IPHYF EV/EBITDA by year
Period	EV/EBITDA
Mar 23	16.87
Mar 23	17.09
Mar 23	21.56
Mar 23	21.66
Mar 23	19.86
Feb 23	20.13
Feb 23	24.96
Feb 23	25.02
Feb 23	24.63
Jan 23	24.38
Jan 23	25.26
Jan 23	24.81
Jan 23	23.33
Dec 22	23.13
Dec 22	16.84
Dec 22	12.03
Dec 22	12.77
Dec 22	13.51
Nov 22	13.51
Nov 22	13.7
Nov 22	11.34
Nov 22	12.23
Oct 22	12.33
Oct 22	12.58
Oct 22	12.69
Oct 22	11.03
Sep 22	10.9
Sep 22	18.6
Sep 22	17.96
Sep 22	3263.08
Sep 22	3401.21
Aug 22	4079.69
Aug 22	3951.32
Aug 22	3782.4
Aug 22	3826.03
Jul 22	4598.36
Jul 22	3636.83
Jul 22	3712.87
Jul 22	3445.47
Jul 22	3318.59
Jun 22	3250.96
Jun 22	2604.43
Jun 22	3613.77
Jun 22	4112.88
May 22	3624.35
May 22	3718.65
May 22	3798.35
May 22	3598.88
Apr 22	3561.1
Apr 22	4008.28
Apr 22	4011.8
Apr 22	4814.22
Apr 22	4.5
Mar 22	4.85
Mar 22	4.8
Mar 22	4.91
Mar 22	4.89
Feb 22	4.65
Feb 22	4.62
Feb 22	4.73
Feb 22	5.58
Jan 22	5.09
Jan 22	5.98
Jan 22	6.14
Jan 22	6.18
Dec 21	6.18
Dec 21	7.64
Dec 21	7.92
Dec 21	7.34
Dec 21	6.39
Nov 21	7.24
Nov 21	7.86
Nov 21	8.04
Nov 21	8.87
Oct 21	8.8
Oct 21	8.9
Oct 21	9.26
Oct 21	9.61
Oct 21	9.47
Sep 21	10.84
Sep 21	13.25
Sep 21	5.34
Sep 21	6.41
Aug 21	1.99
Aug 21	1.75
Aug 21	1.57
Aug 21	1.49
Jul 21	1.46
Jul 21	1.49
Jul 21	1.6
Jul 21	1.77
Jul 21	2.24
Jun 21	1.76
Jun 21	2.21
Jun 21	1.87
Jun 21	1.98
May 21	2.14
May 21	2.15
May 21	2.16
May 21	2.54

Price/Operating Cashflow

IPHYF Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Sep 20	103.65
Aug 20	99.76
Aug 20	104.02
Aug 20	102.73
Aug 20	99.65
Jul 20	101.52
Jul 20	102.54
Jul 20	104.6
Jul 20	105.78
Jul 20	101.8
Jun 20	114.45
Jun 20	107.26
Jun 20	106.54
Jun 20	104.21
May 20	105.91
May 20	122.44
May 20	123.39
May 20	118.45
May 20	112.71
Apr 20	116.88
Apr 20	103.51
Apr 20	91.34
Apr 20	92.25
Mar 20	89.55
Mar 20	71.88
Mar 20	102.05
Mar 20	129.3
Feb 20	135.45
Feb 20	145.22
Feb 20	144.33
Feb 20	134.49
Jan 20	137.59
Jan 20	138.43
Jan 20	139.49
Jan 20	133.27
Jan 20	137.71

Price to Book

IPHYF Price to Book by year
Period	Price to Book
Mar 26	30.83
Mar 26	31.19
Mar 26	30.71
Feb 26	30.17
Feb 26	30.28
Feb 26	30.06
Feb 26	30.2
Jan 26	30.11
Jan 26	30.16
Jan 26	30.76
Jan 26	30.66
Jan 26	30.44
Dec 25	30.31
Dec 25	30.47
Dec 25	26.86
Dec 25	28.36
Nov 25	28.62
Nov 25	28.83
Nov 25	28.56
Nov 25	28.7
Oct 25	28.66
Oct 25	28.54
Oct 25	28.48
Oct 25	28.54
Oct 25	28.26
Sep 25	28.36
Sep 25	28.26
Sep 25	15.64
Sep 25	16.12
Aug 25	16.17
Aug 25	16.12
Aug 25	16.14
Aug 25	10.32
Aug 25	10.37
Jul 25	10.24
Jul 25	10.34
Jul 25	10.28
Jul 25	15.21
Jun 25	15.27
Jun 25	13.85
Jun 25	13.82
Jun 25	11.67
May 25	11.72
May 25	11.7
May 25	11.91
May 25	11.83
May 25	11.77
Apr 25	3.54
Apr 25	3.54
Apr 25	3.54
Apr 25	7.34
Mar 25	7.42
Mar 25	7.44
Mar 25	7.38
Mar 25	7.42
Feb 25	7.75
Feb 25	7.69
Feb 25	7.67
Feb 25	7.79
Jan 25	7.77
Jan 25	7.67
Jan 25	7.83
Jan 25	7.85
Jan 25	7.8
Dec 24	7.72
Dec 24	7.71
Dec 24	7.66
Dec 24	3.36
Nov 24	3.36
Nov 24	3.41
Nov 24	3.37
Nov 24	5.8
Nov 24	5.73
Oct 24	5.75
Oct 24	5.72
Oct 24	5.68
Oct 24	5.66
Sep 24	5.57
Sep 24	5.47
Sep 24	5.76
Sep 24	3.22
Aug 24	3.23
Aug 24	3.19
Aug 24	2.96
Aug 24	2.99
Aug 24	2.75
Jul 24	2.76
Jul 24	2.76
Jun 24	3.96
May 24	3.18
May 24	3.07
Apr 24	3.65
Mar 24	3.55
Mar 24	3.28
Mar 24	3.31
Mar 24	3.43
Jan 24	3.88
Jan 24	3.87
Jan 24	3.85
Jan 24	3.85

No video analysis for this stock yet. Request one from our team.

News: IPHYF

businesswire.com · 14 Aug 2026

Innate Pharma Announces Conference Call and Webcast

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.

businesswire.com · 10 Aug 2026

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding So.

businesswire.com · 10 Aug 2026

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLO.

businesswire.com · 21 Jul 2026

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end and will include data from 76 patients, guiding Phase 1 dose optimization in selected tumor types.